Literature DB >> 34048815

Proton Therapy for Breast Cancer: A Consensus Statement From the Particle Therapy Cooperative Group Breast Cancer Subcommittee.

Robert W Mutter1, J Isabelle Choi2, Rachel B Jimenez3, Youlia M Kirova4, Marcio Fagundes5, Bruce G Haffty6, Richard A Amos7, Julie A Bradley8, Peter Y Chen9, Xuanfeng Ding9, Antoinette M Carr9, Leslie M Taylor9, Mark Pankuch10, Raymond B Mailhot Vega8, Alice Y Ho2, Petra Witt Nyström11, Lisa A McGee12, James J Urbanic13, Oren Cahlon14, John H Maduro15, Shannon M MacDonald3.   

Abstract

Radiation therapy plays an important role in the multidisciplinary management of breast cancer. Recent years have seen improvements in breast cancer survival and a greater appreciation of potential long-term morbidity associated with the dose and volume of irradiated organs. Proton therapy reduces the dose to nontarget structures while optimizing target coverage. However, there remain additional financial costs associated with proton therapy, despite reductions over time, and studies have yet to demonstrate that protons improve upon the treatment outcomes achieved with photon radiation therapy. There remains considerable heterogeneity in proton patient selection and techniques, and the rapid technological advances in the field have the potential to affect evidence evaluation, given the long latency period for breast cancer radiation therapy recurrence and late effects. In this consensus statement, we assess the data available to the radiation oncology community of proton therapy for breast cancer, provide expert consensus recommendations on indications and technique, and highlight ongoing trials' cost-effectiveness analyses and key areas for future research.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 34048815      PMCID: PMC8416711          DOI: 10.1016/j.ijrobp.2021.05.110

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   8.013


  168 in total

1.  The impact of immediate breast reconstruction on the technical delivery of postmastectomy radiotherapy.

Authors:  Sabin B Motwani; Eric A Strom; Naomi R Schechter; Charles E Butler; Gordon K Lee; Howard N Langstein; Steven J Kronowitz; Funda Meric-Bernstam; Nuhad K Ibrahim; Thomas A Buchholz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-06-09       Impact factor: 7.038

2.  Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy.

Authors:  Roshan V Sethi; Helen A Shih; Beow Y Yeap; Kent W Mouw; Robert Petersen; David Y Kim; John E Munzenrider; Eric Grabowski; Carlos Rodriguez-Galindo; Torunn I Yock; Nancy J Tarbell; Karen J Marcus; Shizuo Mukai; Shannon M MacDonald
Journal:  Cancer       Date:  2013-10-02       Impact factor: 6.860

3.  Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease.

Authors:  D E Heron; L T Komarnicky; T Hyslop; G F Schwartz; C M Mansfield
Journal:  Cancer       Date:  2000-06-15       Impact factor: 6.860

4.  Early outcomes of breast cancer patients treated with post-mastectomy uniform scanning proton therapy.

Authors:  Leo Luo; John Cuaron; Lior Braunstein; Erin Gillespie; Atif Kahn; Beryl McCormick; Dennis Mah; Brian Chon; Henry Tsai; Simon Powell; Oren Cahlon
Journal:  Radiother Oncol       Date:  2018-11-07       Impact factor: 6.280

5.  Increasing mastectomy rates among all age groups for early stage breast cancer: a 10-year study of surgical choice.

Authors:  Anthony E Dragun; Bin Huang; Thomas C Tucker; William J Spanos
Journal:  Breast J       Date:  2012-05-21       Impact factor: 2.431

6.  Reirradiation as a component of the multidisciplinary management of locally recurrent breast cancer.

Authors:  Matthew M Harkenrider; Mary R Wilson; Anthony E Dragun
Journal:  Clin Breast Cancer       Date:  2011-04-20       Impact factor: 3.225

7.  Proton Accelerated Partial Breast Irradiation: Clinical Outcomes at a Planned Interim Analysis of a Prospective Phase 2 Trial.

Authors:  Dario Pasalic; Eric A Strom; Pamela K Allen; Tyler D Williamson; Falk Poenisch; Richard A Amos; Wendy A Woodward; Michael C Stauder; Simona F Shaitelman; Benjamin D Smith; George H Perkins; Welela Tereffe; Karen E Hoffman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-09-16       Impact factor: 7.038

8.  Three-dimensional analysis of patterns of locoregional recurrence after treatment in breast cancer patients: Validation of the ESTRO consensus guideline on target volume.

Authors:  Jee Suk Chang; Hwa Kyung Byun; Jun Won Kim; Kyung Hwan Kim; Jeongshim Lee; Yeona Cho; Ik Jae Lee; Ki Chang Keum; Chang-Ok Suh; Yong Bae Kim
Journal:  Radiother Oncol       Date:  2016-11-09       Impact factor: 6.280

9.  The risk for developing a secondary cancer after breast radiation therapy: Comparison of photon and proton techniques.

Authors:  Harald Paganetti; Nicolas Depauw; Andrew Johnson; Rachel Beth Forman; Jackson Lau; Rachel Jimenez
Journal:  Radiother Oncol       Date:  2020-05-25       Impact factor: 6.280

10.  Validation and Modification of a Prediction Model for Acute Cardiac Events in Patients With Breast Cancer Treated With Radiotherapy Based on Three-Dimensional Dose Distributions to Cardiac Substructures.

Authors:  Veerle A B van den Bogaard; Bastiaan D P Ta; Arjen van der Schaaf; Angelique B Bouma; Astrid M H Middag; Enja J Bantema-Joppe; Lisanne V van Dijk; Femke B J van Dijk-Peters; Laurens A W Marteijn; Gertruida H de Bock; Johannes G M Burgerhof; Jourik A Gietema; Johannes A Langendijk; John H Maduro; Anne P G Crijns
Journal:  J Clin Oncol       Date:  2017-01-17       Impact factor: 44.544

View more
  7 in total

Review 1.  Hypothalamic syndrome.

Authors:  Hermann L Müller; Maithé Tauber; Elizabeth A Lawson; Jale Özyurt; Brigitte Bison; Juan-Pedro Martinez-Barbera; Stephanie Puget; Thomas E Merchant; Hanneke M van Santen
Journal:  Nat Rev Dis Primers       Date:  2022-04-21       Impact factor: 52.329

Review 2.  Hypofractionated proton therapy in breast cancer: where are we? A critical review of the literature.

Authors:  Daniela Alterio; Eliana La Rocca; Maria Cristina Leonardi; Barbara Alicja Jereczek-Fossa; Stefania Volpe; Anna Maria Camarda; Alessia Casbarra; William Russell-Edu; Maria Alessia Zerella; Roberto Orecchia; Viviana Galimberti; Paolo Veronesi
Journal:  Breast Cancer Res Treat       Date:  2022-01-13       Impact factor: 4.872

Review 3.  Risk Management for Radiation-Induced Cardiovascular Disease (RICVD): The 2022 Consensus Statement of the Taiwan Society for Therapeutic Radiology and Oncology (TASTRO) and Taiwan Society of Cardiology (TSOC).

Authors:  Long-Sheng Lu; Yen-Wen Wu; Joseph Tung-Chieh Chang; Wei-Ting Chang; Ting-Hsing Chao; Helen Hai-Wen Chen; Yu-Jen Chen; Kai-Hung Cheng; Wen-Lin Hsu; Chung-Lieh Hung; Sung-Hsin Kuo; Ji-An Liang; Hung-Ju Lin; Ping-Yen Liu; Wen-Shan Liu; Yen-Wen Liu; Pei-Wei Shueng; Chao-Yung Wang; Charles Jia-Yin Hou; Jeng-Fong Chiou
Journal:  Acta Cardiol Sin       Date:  2022-01       Impact factor: 2.672

Review 4.  Myocardial Ischemia Related to Common Cancer Therapy-Prevention Insights.

Authors:  Minerva Codruta Badescu; Oana Viola Badulescu; Dragos Viorel Scripcariu; Lăcrămioara Ionela Butnariu; Iris Bararu-Bojan; Diana Popescu; Manuela Ciocoiu; Eusebiu Vlad Gorduza; Irina Iuliana Costache; Elena Rezus; Ciprian Rezus
Journal:  Life (Basel)       Date:  2022-07-12

5.  Incidence of clinical lymphedema in breast cancer patients treated with adjuvant proton-based radiotherapy.

Authors:  Mutlay Sayan; Imraan Jan; Irina Vergalasova; Sarah S Kilic; Shicha Kumar; Bruce Haffty; Nisha Ohri
Journal:  Rep Pract Oncol Radiother       Date:  2022-07-29

6.  Planning and Treatment Recommendations for Breast Proton Therapy From a Single Center's Experience.

Authors:  Rachel B Ger; Khadija Sheikh; Emile Gogineni; Bethlehem Floreza; Victoria Croog; Heng Li; Jean L Wright
Journal:  Adv Radiat Oncol       Date:  2022-09-09

7.  Hypofractionated Whole Breast Irradiation and Boost-IOERT in Early Stage Breast Cancer (HIOB): First Clinical Results of a Prospective Multicenter Trial (NCT01343459).

Authors:  Gerd Fastner; Roland Reitsamer; Christoph Gaisberger; Wolfgang Hitzl; Bartosz Urbański; Dawid Murawa; Christiane Matuschek; Wilfried Budach; Antonella Ciabattoni; Juliann Reiland; Marie Molnar; Cristiana Vidali; Claudia Schumacher; Felix Sedlmayer
Journal:  Cancers (Basel)       Date:  2022-03-09       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.